Semaglutide Vial Overfill: Why There's Extra and Whether You Can Use It
You've been carefully drawing your prescribed dose from your compounded semaglutide vial, tracking your usage, and you notice something: after your last scheduled dose, there's still medication left in the vial. The label says 2 mL, but it looks like there's closer to 2.3 mL in there. Is that extra medication safe to use? Was there a compounding error? Or is this intentional?
Why Overfill Exists
Overfill in injectable medication vials is not an accident — it's a deliberate pharmaceutical practice mandated by USP standards. USP General Chapter <1> specifies that injectable vials must contain enough excess volume to permit withdrawal and administration of the labeled volume. The rationale is straightforward: it's physically impossible to withdraw every last drop of liquid from a vial with a standard syringe and needle. Some medication always remains in the dead space — the hub of the needle, the connection between the needle and syringe, and the liquid clinging to the vial walls.
To ensure that patients can reliably withdraw the full labeled dose, pharmacies (and commercial manufacturers) intentionally add excess volume. The amount of overfill varies by vial size:
- Vials labeled 1 mL: Typically contain 0.10-0.15 mL excess
- Vials labeled 2 mL: Typically contain 0.15-0.25 mL excess
- Vials labeled 5 mL: Typically contain 0.30-0.50 mL excess
These overfill amounts are approximate — USP provides minimum excess volumes, and individual pharmacies may add slightly more to account for their specific vial and stopper configurations.
Can You Use the Overfill?
This is where practice and guidance diverge. The overfill exists to ensure you can get your last labeled dose out — it's not intended as a "bonus dose." However, the medication in the overfill is the same formulation, at the same concentration, compounded at the same time as the rest of the vial. Pharmacologically, it's identical.
Arguments For Using It
- The overfill medication is the same quality as the rest of the vial
- Discarding usable medication is wasteful, especially at $200+/month
- If you can draw a full dose from the remaining volume, the dose is accurate
- The overfill falls within the vial's beyond-use dating — it was compounded at the same time
Arguments Against Using It
- The overfill was not intended as a therapeutic dose — your prescriber wrote for a specific number of doses per vial
- Using the overfill extends the time between refills, which could mask adherence patterns your prescriber tracks
- The last withdrawal from a multi-dose vial draws from the bottom of the vial, where particulate matter (if any) may have settled
- Each additional needle puncture through the stopper increases contamination risk, even with preservative
If you can draw a complete, accurately measured dose from the remaining overfill volume, and the vial is still within its 28-day post-puncture window and before its beyond-use date, using that dose is a reasonable patient decision. But don't scrape the bottom of the vial for a partial dose — an inaccurate dose is worse than no dose. And don't let the overfill extend your vial usage beyond 28 days from first puncture.
What Your Pharmacy Knows
Compounding pharmacies are aware that their vials contain overfill — they put it there intentionally. Some pharmacies account for overfill in their dosing guides (e.g., "this vial contains enough medication for 4 doses plus overfill"). Others label the vial strictly by content volume without referencing the overfill. If you're unsure, ask your pharmacy: "Does the labeled volume account for overfill, or is the labeled volume the deliverable volume?"
Overfill and Cost
Patients paying $200-400/month for compounded semaglutide understandably want to use every drop. Over the course of a year, the overfill from monthly vials could add up to an extra week or two of medication — a meaningful amount both clinically and financially. This is a pragmatic consideration that most prescribers and pharmacists understand.
Some telehealth providers explicitly acknowledge overfill in their patient materials, noting that patients may get "an extra dose or two" from each vial depending on how efficiently they draw their doses. Others prefer patients discard the overfill to maintain strict adherence to the prescribed dosing schedule.
The 28-Day Rule Still Applies
Regardless of whether you use the overfill, the 28-day rule for multi-dose vials preserved with bacteriostatic water does not extend because there's medication remaining. If you opened the vial 28 days ago, the preservative system's effectiveness is no longer guaranteed — discard the vial even if there's usable volume left. The beyond-use date on the label also overrides any remaining volume.
Providers With Transparent Vial Documentation
Embody
Injectable semaglutide through established 503A pharmacy partnerships. Clinician-monitored dosing with direct pharmacy fulfillment.
Compounded medications are not FDA-approved.
Learn More Paid linkGala
Flat-rate injectable GLP-1 program — same price at every dose level. No price jumps during titration.
Compounded medications are not FDA-approved.
Learn More Paid linkSHED
Compounded semaglutide and tirzepatide with clinical monitoring. Multiple dose strengths available through 503A pharmacy partners.
Compounded medications are not FDA-approved.
Learn More Paid linkCompare GLP-1 Providers Side by Side
See pricing, pharmacy credentials, and delivery formats for verified telehealth providers.
View Provider Comparison →Sources
- USP. "General Chapter <1> Injections and Implanted Drug Products — Excess Volume Requirements." United States Pharmacopeia.
- FDA. "Guidance for Industry: Container Closure System Guidance for Parenteral Drug Products." Updated 2025.
- ISMP. "Overfill in Injectable Vials: Safety Considerations and Patient Communication." Institute for Safe Medication Practices, 2024.
Affiliate Disclosure: Some links on this page are paid affiliate links. If you sign up through them, we may earn a commission at no extra cost to you. This does not influence our editorial content or provider evaluations.
Medical Disclaimer: This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
FDA Notice: Compounded medications referenced in this article are not FDA-approved. Only brand-name GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro) carry FDA approval for their indicated uses.